Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 28.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,640 shares of the company's stock after selling 2,256 shares during the quarter. Intech Investment Management LLC's holdings in Medpace were worth $1,883,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of MEDP. Westwind Capital increased its stake in shares of Medpace by 800.1% during the second quarter. Westwind Capital now owns 380,929 shares of the company's stock worth $156,886,000 after buying an additional 338,610 shares during the period. Clearbridge Investments LLC grew its holdings in Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after acquiring an additional 143,481 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock worth $182,692,000 after acquiring an additional 122,800 shares in the last quarter. AQR Capital Management LLC grew its holdings in Medpace by 62.3% during the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company's stock worth $127,941,000 after acquiring an additional 119,257 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Medpace by 1,028.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 116,683 shares of the company's stock worth $48,056,000 after acquiring an additional 106,343 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several analyst reports. Robert W. Baird boosted their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a report on Monday. William Blair reiterated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Redburn Atlantic started coverage on shares of Medpace in a report on Monday, October 14th. They issued a "buy" rating and a $404.00 target price for the company. Finally, TD Cowen lowered their target price on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $380.56.

Medpace Stock Up 1.8 %

NASDAQ:MEDP traded up $6.16 during trading hours on Monday, reaching $343.91. 102,995 shares of the company's stock were exchanged, compared to its average volume of 284,450. The firm has a market capitalization of $10.69 billion, a price-to-earnings ratio of 29.58, a P/E/G ratio of 1.87 and a beta of 1.37. The company has a 50-day moving average of $340.14 and a 200 day moving average of $373.03. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts' expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.22 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.